Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026

IMMUNIC, INC.

2026-Q1 EPS reported -$1.08 vs consensus -$0.93 ▼ miss (-16.0%)

Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.
Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.
Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.
Key European patent granted for vidofludimus calcium with potential exclusivity into 2043.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

IMMUNIC, INC. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended March 31, 2026, and providing a corporate update

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-26-000593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.